ARS Pharmaceuticals (SPRY) Return on Assets (2021 - 2026)

ARS Pharmaceuticals (SPRY) has 6 years of Return on Assets data on file, last reported at 0.02% in Q1 2026.

• For the quarter ending Q1 2026, Return on Assets fell 1.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, down 1.0% from the prior year.
• Return on Assets declined to 0.02% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Assets ranged from a high of 0.0% in Q3 2022 to a low of 3.86% in Q4 2023.
• A 5-year average of 0.88% and a median of 0.01% in 2025 frame the typical range for Return on Assets.
• Across the five-year window, Return on Assets slumped 386 bps in 2023 and jumped 385 bps in 2024, its largest moves.
• Tracing SPRY's Return on Assets over 5 years: stood at 0.0% in 2022, then slumped by 192501 bps to 3.86% in 2023, then surged by 100 bps to 0.01% in 2024, then declined by 27 bps to 0.01% in 2025, then dropped by 30 bps to 0.02% in 2026.
• Business Quant data shows SPRY's Return on Assets at 0.02% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.